What is the revenue of Soleno?

Written by Editorial Team | Last Updated: August 2026

Soleno Therapeutics, Inc. reports a trailing twelve-month revenue of approximately $190.4 million USD (translating to over ₹16 billion in equivalent global tracking metrics), reflecting strong commercial adoption following the market approval and rollout of its flagship pharmaceutical treatment VYKAT XR. The biopharmaceutical enterprise secures robust top-line streams through specialized therapeutic sales, achieving profitable operations and significant cash flow generation.

Related FAQs

Class-action lawsuits involving Soleno Therapeutics, Inc.

Mind Medicine, commonly known as MindMed, commands a multi-billion-dollar market capitalization, reflecting high investor enthusiasm within the clinical-stage biopharmaceutical sector.

Lucid Group, traded under the ticker LCID, maintains a market capitalization fluctuating around the multi-billion-dollar range.

Soleno Therapeutics, Inc. maintains a specialized market capitalization valued in the tens of millions to over a hundred million U.S. dollars, reflecting its status as a clinical-stage biopharmaceutical enterprise.

Neurocrine Biosciences completed a definitive acquisition agreement to purchase Soleno Therapeutics for a total equity valuation of approximately 2.9 billion dollars in cash.

Hyperphagia, an abnormally intense and persistent sensation of hunger often associated with rare genetic disorders like Prader-Willi syndrome, has historically relied primarily on strict environmental food security and behavioral management.

Soleno Therapeutics operates as a fully transparent, SEC-registered public biotechnology corporation listed on major stock exchanges, adhering strictly to federal reporting standards, corporate governance rules, and pharmaceutical industry regulation...

Soleno Therapeutics achieved a major regulatory milestone when its flagship lead product candidate, VYKAT XR extended-release tablets, received official approval from the United States Food and Drug Administration.

Investing in NIO involves assessing its position as an early pioneer and technology leader in premium smart electric vehicles and automated battery exchange services.

VYKAT XR (diazoxide choline extended-release tablets), developed by Soleno Therapeutics, received FDA approval as an essential oral treatment indicated to manage severe hyperphagia in adult and pediatric patients aged 4 years and older with Prader-Wi...

Soleno Therapeutics Inc, trading under the ticker SLNO, is a biopharmaceutical company that has drawn significant market attention following major corporate acquisition developments and the successful commercial launch of its flagship therapeutic pro...

SmartBank operates as a growing commercial community bank serving regions across the Southeastern United States, establishing a distinct operating model when evaluated against national banking mega-corporations.

Soleno Therapeutics, Inc. was originally incorporated in Delaware under the name Capnia, Inc. before undergoing a major strategic pivot and corporate rebranding.

Soleno Therapeutics Inc, trading under the ticker symbol SLNO, was a publicly traded biopharmaceutical company listed on the Nasdaq stock exchange.